THC Farmaceuticals, Inc.
CBDG · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.00 | 1.25 | 0.31 |
| FCF Yield | 350.52% | 8.81% | -1.29% | -0.14% |
| EV / EBITDA | -12.84 | 8.72 | -79.61 | -16.44 |
| Quality | ||||
| ROIC | -1.09% | -0.31% | -0.69% | -1.54% |
| Gross Margin | 0.00% | 61.92% | 57.39% | 100.00% |
| Cash Conversion Ratio | -42.44 | 0.74 | 1.40 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 9.70% | -39.71% | -14.71% |
| Free Cash Flow Growth | 99.92% | 2,803.15% | -433.09% | 98.36% |
| Safety | ||||
| Net Debt / EBITDA | -5.59 | 0.33 | -22.32 | -2.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 23,221.85 | 92,202.17 | 30,386.74 |